<DOC>
	<DOC>NCT01697605</DOC>
	<brief_summary>This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).</brief_summary>
	<brief_title>A Phase I Study of Oral BGJ398 in Asian Patients</brief_title>
	<detailed_description>This is a multi-center, open label, dose finding, phase I study of oral single agent BGJ398, administered on a continuous once and/or twice daily schedule.</detailed_description>
	<criteria>Patients with advanced solid tumors with FGFR alteration Eastern Cooperative Oncology Group (ECOG) performance status 02 Adequate organ function Patients with untreated and/or symptomatic metastatic Central Nerve System (CNS) disease Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I, open-label, dose escalation, BGJ398, Japanese, Asian, FGF-R</keyword>
</DOC>